Theranostics Certification – Legacy Providers
19 September 2023
The process for recognition of retrospective/legacy experience in Theranostics for qualified practicing Nuclear Medicine Specialists has been finalised by the RACP College Education Committee (CEC) which oversees the Committee for Joint College Training (CJCT) – stating that the process will be managed by the AANMS and its Theranostics Committee, along with the CJCT in Nuclear Medicine.
The principles for documentation and validation of legacy experience as a basis for certification are modelled upon those for PET, that were developed in consultation with the AANMS, RACP and RANZCR. This does not alter access to items which are currently listed on the MBS as of 1 September 2023.
Initial round Applications are due back to AANMS by 16 October 2023.
It is appreciated that this has been a lengthy development process, so the decision has been made to have an initial round of applications prior to the November 2023 meeting of the CJCT, therefore applications are due back to AANMS by 16 October 2023. There is no need for concern, or rush, as there will be regular application periods open each year, with this legacy provider pathway open until 2030.
Follow these links for details on how the application process works and for the application form.
Please submit the application form to: theranostics.certification@aanms.org.au, by C.O.B. 16 October 2023. You will receive an acknowledgement and receipt/tax invoice after payment is confirmed.
It is anticipated that there may be an initial flurry of applications, so please be aware that some may be held over until the next meeting of the CJCT.
Congratulations to all involved in developing this process, as Australia continues to set the standard for practice in this field.
Amendments to the Medicare Benefits Schedule from 1 July
Changes to the Diagnostic Imaging Services Table and Changes to Therapeutic Nuclear Medicine
30 June 2023
Changes to the DI Services Table and Changes to Therapeutic NM are now available on MBSonline. The following links may be of assistance in understanding the upcoming changes:
The XMLs and link to the July news page can be found here.
Download the fact sheets:
Factsheet – Changes to DI Services Table
Factsheet – Changes to Therapeutic Nuclear Medicine
Australian National Diagnostic Reference Levels for NM
15 May 2023
In 2020 AANMS agreed to participate in a review of the National Diagnostic Reference Levels (NDRLs) for nuclear medicine. The Liaison Panel reviewing the NDRLs included representatives from ARPANSA, the AANMS, the ANZSNM, the Australian Diagnostic Imagine Association (ADIA), the Australasian College of Physical Scientists and Engineers in Medicine (ACPSEM), and the Diagnostic Imaging Accreditation Scheme (DIAS) Advisory Committee.
The Liaison Panel has agreed on recommendations to revise the existing adult nuclear medicine NDRLs, based on data submitted to a national survey conducted between October 2021 and March 2022. In addition to revising the DRL values, the Panel recommends that:
- The number of DRLs for general nuclear medicine is reduced to focus on the most common procedures
- DRLs be introduced for 68Ga DOTA-TATE and prostate cancer positron emission tomography (PET) procedures (68Ga PSMA and 18F DCFPyL)
- DRLs for the CT component of hybrid imaging be defined in terms of volume computed tomography dose index (CTDIvol) in addition to dose length product (DLP), (the existing DRLs are only in terms of DLP)
- The DRLs for the CT component of PET/CT imaging are categorized based on arm positioning.
Transitional arrangements relating to Diagnostic Imaging Accreditation Scheme (DIAS) requirements will be discussed with the DIAS Advisory Committee and the Australian Commission on Safety and Quality in Health Care (ACSQHC). It is anticipated that a transition period will apply after the announcement of the revised NDRLs. During the transition period, comparisons against either the previous NDRLs or the revised NDRLs would be accepted for the purposes of compliance with DIAS Standard 3.2.
ARPANSA is confident that the data considered by the Liaison Panel is a good reflection of current practice at Australian nuclear medicine imaging facilities. The AANMS Board has endorsed these NDRLs for nuclear medicine and recommends to AANMS members that they use the ARPANSA data to inform their practices.
The AANMS Board thanks those AANMS members, including A/Prof. George Larcos, for their input into this review.
The ARPANSA documents can be downloaded below:
Proposed Revisions
Nuclear_Medicine_Quantiles
Revised_NM_DRLs_Summary_Tables
Nuclear Medicine in the News – Targeted Alpha Therapy
31 March 2023
The Australian Financial Review has a prominent article on the world-leading research conducted by Professor Michael Hofman, Dr Mohammad Haskali and colleagues at the Peter MacCallum Cancer Centre, Essen University Hospital Germany and the University of California at Los Angeles and San Francisco.
The team’s development of what is described as “liquid radiation” or targeted alpha therapy is hailed as a new pillar in the treatment of cancer, and demonstrates that among the groups working in this field, Australia is a leader. AANMS President, Associate Professor Sze Ting Lee, says, “The fact that it is an Australian innovation is also exciting. Australia is definitely punching above its weight in developing nuclear medicine technology for the world.”
AANMS President’s interview: 25 years of non-indexation of nuclear medicine impeding access and affordability
16 March 2023
The AANMS President’s Australian Health Journal interview ahead of the budget has been released.
Click on the following links to view:
Pre-Budget Submission: Strengthening Medicare Through the Re-Indexation of Nuclear Medicine Items on MBS
10 February 2023
Australian patients requiring nuclear medicine services are facing higher out of pocket costs as a result of inaction from successive governments to adequately fund and index nuclear medicine items on Medicare for more than 20 years.
Read the submission here.
Australian Meetings 2024
NOTE: We will continue to keep these lists updated, but please check with the organising body before making any plans.
Masterclass in Amyloid PET for Management & Diagnosis of Alzheimers Disease
14 October 2024
11am-4.30pm AEDT
Kenneth Meyer Auditorium, Kenneth Meyer Building, University of Melbourne
Free educational workshop
Click here to register
RANZCR 2024 Annual Scientific Meeting
17 – 19 October 2024
Perth Convention & Exhibition Centre, Perth WA
Website
International Meetings 2024
IAEA International Conference on Hybrid Imaging (IPET 2024)
7 – 11 October 2024
Vienna, Austria
Download the information document
EANM 37th Annual Congress
19 – 23 October 2024
Hamburg, Germany
Website
ICPO Theranostics Summit 2024
14-15 November 2024
Virtual
Further information
RSNA 2024 – registration opens July 2024
1 – 5 December 2024
McCormick Place Convention Centre, Chicago, USA
Further information
Australian Meetings 2025
NOTE: We will continue to keep these lists updated, but please check with the organising body before making any plans.
ANZSNM 55th Annual Scientific Meeting
23 – 25 May 2025
Melbourne Convention and Exhibition Centre
Further information
CSANZ 73rd Annual Scientific Meeting
14 – 17 August 2025
Brisbane Convention and Exhibition Centre
Further information
RANZCR Annual Scientific Meeting
23 – 25 October 2025
Melbourne Convention and Exhibition Centre
Website
International Meetings 2025
SNMMI Annual Meeting 2025
21 – 24 June 2025
New Orleans, Louisiana, USA
Website